Plant Name: Tadehagi triquetrum
Taxonomic Information:
Plant ID: NPO19353
Plant Latin Name: Tadehagi triquetrum
Taxonomy Genus: Tadehagi
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
714511
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Thailand; Indonesia; India; China; LaosTraditional Medicine System:
Indian Folk; TCMGeographical Distribution:
India; Indonesia; China; Thailand; Laos
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HCAR2; | |
| SCN2A; SCN11A; SCN8A; SCN4A; SCN9A; SCN1A; SCN3A; | |
| CA2; CA14; CA7; CA1; CA12; CA9; | |
| NR1H4; | |
| SLCO1B1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Voltage-gated sodium channel | SCN2A | Sodium channel protein type II alpha subunit | Q99250 | CHEMBL4187 |
| Voltage-gated sodium channel | SCN11A | Sodium channel protein type XI alpha subunit | Q9UI33 | CHEMBL5167 |
| Voltage-gated sodium channel | SCN8A | Sodium channel protein type VIII alpha subunit | Q9UQD0 | CHEMBL5202 |
| Voltage-gated sodium channel | SCN4A | Sodium channel protein type IV alpha subunit | P35499 | CHEMBL2072 |
| Voltage-gated sodium channel | SCN9A | Sodium channel protein type IX alpha subunit | Q15858 | CHEMBL4296 |
| Voltage-gated sodium channel | SCN1A | Sodium channel protein type I alpha subunit | P35498 | CHEMBL1845 |
| Voltage-gated sodium channel | SCN3A | Sodium channel protein type III alpha subunit | Q9NY46 | CHEMBL5163 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.711E-13 | 1.526E-09 | CA1, CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0051179; localization | GO:0035725; sodium ion transmembrane transport | 9.522E-13 | 1.728E-09 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.245E-11 | 9.280E-08 | CA1, CA12, CA2, CA7, CA9 |
| MF | GO:0005215; transporter activity | GO:0005244; voltage-gated ion channel activity | 1.172E-10 | 1.343E-07 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
| MF | GO:0005215; transporter activity | GO:0008381; mechanosensitive ion channel activity | 4.255E-09 | 2.808E-06 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
| BP | GO:0051179; localization | GO:0034765; regulation of ion transmembrane transport | 2.328E-08 | 1.267E-05 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
| CC | GO:0044464; cell part | GO:0033268; node of Ranvier | 2.109E-07 | 9.004E-05 | SCN1A, SCN2A, SCN8A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.929E-06 | 7.119E-04 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 9.631E-06 | 3.226E-03 | CA1, CA2 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.884E-05 | 9.514E-03 | CA2, CA7 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.041E-05 | 9.737E-03 | CA1, CA12, CA2, CA7, CA9, NR1H4 |
| CC | GO:0044425; membrane part | GO:0001518; voltage-gated sodium channel complex | 1.969E-19 | 4.287E-15 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
| MF | GO:0005215; transporter activity | GO:0005248; voltage-gated sodium channel activity | 1.401E-17 | 1.017E-13 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
| BP | GO:0009987; cellular process | GO:0019228; neuronal action potential | 1.160E-16 | 5.053E-13 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.538E-16 | 2.010E-12 | CA1, CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0065007; biological regulation | GO:0086010; membrane depolarization during action potential | 1.530E-15 | 4.760E-12 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.111E-15 | 9.995E-15 | CA12, CA1, CA2, CA7, CA9, CA14 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04742 | Taste transduction | 3.712E-05 | 1.114E-04 | SCN9A, SCN2A, SCN3A |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.323E-05 | 1.045E-04 | SLCO1B1, CA2, NR1H4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | SCN1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | SCN1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | SCN1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HCAR2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nervous and musculoskeletal disorders | R25-R29 | SCN4A; |
| G00-G99: Diseases of the nervous system G00-G99 | Peripheral neuropathy | G64 | SCN1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | SCN1A; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | SCN1A; HCAR2; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | SCN1A; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | SCN1A; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HCAR2; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | SCN1A; |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | SCN1A; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | SCN9A; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Seizures occurring during or following neurosurgery | G40 | SCN1A; |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | SCN1A; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | SCN1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | SCN1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Seizures associated with lennox-Gastaut syndrome | R56.9 | SCN1A; |
| C00-D49: Neoplasms | Gastric cancer | C16 | SCN1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | SCN1A; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | SCN9A; SCN4A; SCN1A; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Oxytocic | O00-O99 | SCN1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HCAR2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | SCN1A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | SCN1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | SCN1A; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HCAR2; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Local or regional analgesia and anesthesia | R20.0 | SCN1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SCN1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | SCN1A; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | SCN1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | SCN1A; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Seizures | G40, P90, R56 | SCN1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | SCN1A; |
| NA: NA | Seizure disorder | NA | SCN1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | SCN1A; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; |
| A00-B99: Certain infectious and parasitic diseases | Infections with sarcoptes scabiei | B86 | SCN1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SCN1A; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
